Executive summary

Patient testimonials can be useful educational and marketing content, but testimonials about compounded drugs are regulated advertising. A testimonial can create express and implied claims about a product's safety, effectiveness, expected outcomes, comparative performance, and appropriateness for a condition. The principal federal rule is straightforward: advertising or promotion of a compounded drug may not be false or misleading. FDCA § 502(bb), 21 U.S.C. § 352(bb) (added by the Drug Quality and Security Act, Pub. L. No. 113-54, § 103(b) (2013)).

The 503A/503B distinction does not create a testimonial safe harbor. The relevant differences concern the compounding, prescription, distribution, labeling, and regulatory framework. Both 503A compounders and 503B outsourcing facilities should apply the same core promotional controls: truthful presentation, substantiation for product claims, transparent disclosures, careful review of implied claims, and appropriate privacy authorization for identifiable patient stories.

This alert addresses federal law and the principal Florida overlay. It is intended as a general compliance resource. Best practice would be to have each campaign or testimonial reviewed by counsel.

The governing promotional standard

A compounded drug is deemed misbranded if its advertising or promotion is false or misleading in any particular. That prohibition applies broadly to marketing communications, including a pharmacy's or telehealth platform's website, social media content, paid advertising, video, email campaigns, landing pages, and influencer or patient testimonial campaigns. FDCA § 502(bb), 21 U.S.C. § 352(bb). FDA actively enforces this provision: beginning in 2025, it issued warning letters to dozens of telehealth platforms and compounding operations, citing section 502(bb) misbranding for misleading online promotion of compounded GLP-1 and other products.

Accordingly, a genuine patient statement may still be unlawful or risky when the overall presentation communicates an unsupported takeaway. The analysis is not confined to the testimonial's literal wording. Captions, editing, headline text, before and after images, product photos, calls to action, surrounding context, and audience targeting can all affect the claims a reasonable consumer takes from the promotion.

What makes a testimonial risky?

Efficacy, safety, and condition claims

Testimonials commonly convey claims such as:

·         “This medication worked when nothing else did.”

·         “I lost 30 pounds in two months.”

·         “It eliminated my symptoms.”

·         “It was safer or better than the brand-name alternative.”

·         “Anyone with this condition should try it.”

Those statements may imply that the compounded product reliably produces a specified result, is safe for a population, treats a condition, or outperforms an approved drug. A patient's experience alone is not adequate substantiation for a general product claim. Health-related advertising claims require support appropriate to the claim, commonly described by the FTC as competent and reliable scientific evidence. FTC, Health Claims.

Typicality and exceptional results

A testimonial featuring an unusually favorable outcome can be misleading if consumers would understand it as typical. The FTC's endorsement guidance requires advertisers to have support for implied typical-results claims or to provide a clear disclosure of the generally expected performance in the circumstances shown. A generic “results may vary” disclosure is not a substitute for identifying the generally expected outcome where the advertisement conveys a specific performance claim. FTC, Endorsement Guides, 16 C.F.R. Part 255 (rev. 2023).

Material connections and review practices

Disclose any material connection between the patient or endorser and the advertiser clearly and conspicuously. Examples include compensation, free or discounted medication, account credits, referral benefits, affiliate payments, or another material incentive. The testimonial must reflect the endorser's honest views and actual experience. The advertiser should also avoid generating fake reviews, selectively publishing only favorable paid reviews, or suppressing authentic negative reviews through deceptive means. FTC, Endorsement Guides, 16 C.F.R. Part 255 (rev. 2023). Many of these practices; creating or selling fake reviews or testimonials, procuring reviews conditioned on expressing a particular sentiment, and suppressing negative reviews, now also independently violate the FTC's Rule on the Use of Consumer Reviews and Testimonials, 16 C.F.R. Part 465, which authorizes civil penalties for knowing violations.

Compounded drugs are not FDA-approved

Marketing should not state or imply that a compounded product has been approved by FDA. FDA explains that compounded drugs are not FDA approved and that FDA does not independently verify their safety, effectiveness, or quality before marketing. This point is especially important when an ad uses visual branding, comparison language, or references to an approved drug that could cause consumers to believe the compounded product is the approved product or has the same regulatory status. FDA, Compounding Laws and Policies.

A clear and accurate explanation that the product is compounded may be necessary in context, but a disclaimer cannot cure an otherwise deceptive efficacy, safety, or comparative claim.

Does the answer differ for 503A and 503B products?

Not on the fundamental testimonial rules. Both types of compounded products are subject to the federal prohibition on false or misleading advertising or promotion. The distinction matters because it changes the surrounding regulatory and factual context.

The statutory framework recognizes that a 503B outsourcing facility may or may not obtain prescriptions for identified individual patients, while 503A compounding is generally connected to patient-specific prescriptions. FDCA § 502(bb), 21 U.S.C. § 352(bb) ; FDA, FD&C Act Provisions That Apply to Human Drug Compounding. Because a 503B facility may also distribute for office stock, a patient story used in 503B marketing can read less like an individual account and more like a broad product advertisement, so the overall impression of the promotion should be reviewed with that in mind.

The resulting practical difference is contextual, not categorical. A 503A testimonial may create a stronger implication of an individualized clinical relationship or suitability determination. A 503B testimonial used in broader marketing may create a stronger implication of a generalizable product claim. In either case, the advertiser should substantiate the claims reasonably conveyed and avoid an ad that obscures the product's compounded status.

HIPAA and patient authorization

When an identifiable patient story is used by a covered pharmacy, provider, or related covered entity for marketing, the use likely involves protected health information. Obtain a valid HIPAA authorization before publishing the testimonial if it identifies the individual directly or indirectly through name, image, diagnosis, treatment, medication, outcome, or other identifying information. If the marketing involves direct or indirect remuneration from a third party, the authorization must state that remuneration is involved. HHS OCR, When Is Authorization Required for Marketing?. See 45 C.F.R. § 164.508(a)(3).

A general consent to treatment or privacy practices acknowledgment is not a marketing authorization. De-identification can reduce HIPAA issues, but it does not eliminate FDA, FTC, state law, contract, or publicity-right concerns.

Pre-publication checklist

Before publishing, reposting, boosting, or paying to distribute a patient testimonial, confirm the following:

1.  Product identification: The content accurately identifies the compounded product and does not imply that it is FDA approved or the same as an approved branded product.

2.   Claim inventory: The pharmacy has identified every express and implied safety, efficacy, comparative, condition related, speed of results, and typicality claim.

3.   Substantiation: The pharmacy has support appropriate to each claim; the patient's experience is not being used as the sole substantiation for a general health claim.

4.  Typicality: Exceptional outcomes are not presented as typical without support, and any generally expected results disclosure is clear, conspicuous, and tailored to the claim.

5.   Endorser integrity: The testimonial reflects the patient's genuine experience and has not been materially altered to create a different claim.

6.   Incentive disclosure: Payment, free product, discounts, credits, referral benefits, or other material connections are clearly disclosed.

7.   Privacy authorization: A valid HIPAA marketing authorization is in place when needed for identifiable patient information.

8.   Whole-ad review: Compliance personnel review the full advertisement, including visuals, captions, hashtags, landing page, target audience, and call to action.

9.   Recordkeeping: Retain the authorization, final creative, disclosures, substantiation file, endorser agreement, incentive information, and approval record.

Conclusion

Testimonials about compounded drugs are not prohibited solely because the product is compounded or because it is a 503A or 503B product. They should, however, be treated as high-risk healthcare advertising. The central question is whether the complete promotion truthfully and adequately communicates what the product is, what results can reasonably be expected, and what the pharmacy has support to claim.

For most campaigns, a disciplined pre-publication review is preferable to trying to correct a problematic claim through disclaimers after the creative is complete.

Selected authorities and resources

·         FDCA § 502(bb), 21 U.S.C. § 352(bb) (added by the Drug Quality and Security Act, Pub. L. No. 113-54, § 103(b) (2013))

·         FDA, Compounding Laws and Policies

·         FDA, FD&C Act Provisions That Apply to Human Drug Compounding

·         FTC, Endorsement Guides, 16 C.F.R. Part 255 (rev. 2023)

·         FTC, Rule on the Use of Consumer Reviews and Testimonials, 16 C.F.R. Part 465

·         HIPAA marketing authorization rule, 45 C.F.R. § 164.508(a)(3)

·         FDA, 2025 compounded GLP-1 warning letters (example)

·         FTC, Health Claims

·         HHS OCR, When Is Authorization Required for Marketing?

·         Fla. Stat. § 465.024

·         Fla. Stat. § 499.0054